The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 701–800 of 999
Bayat, M., Asemani, Y., & Najafi, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107679 · Cited by 15
Enoksson, S. L., Bergman, P., Klingström, J., Boström, F., Rodrigues, R. D. S., Winerdal, M. E., & Marits, P. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113159 · Cited by 13
T cell responses to SARS-CoV-2 in humans and animals
Mattoo, S.-U.-S., & Myoung, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1624-z · Cited by 13
Pérez‐Gómez, A., Gasca‐Capote, C., Vitallé, J., Ostos, F. J., Serna‐Gallego, A., Trujillo‐Rodríguez, M., Muñoz‐Muela, E., Giráldez‐Pérez, T., Praena‐Segovia, J., Navarro-Amuedo, M. D., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.802 · Cited by 12
Goyal, A., Duke, E. R., Ojeda, E. F. C., & Schiffer, J. T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.21.163550 · Cited by 13
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573647 · Cited by 13
Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2
Wirsching, S., Harder, L. H., Heymanns, M., Gröndahl, B., Hilbert, K., Kowalzik, F., Meyer, C. U., & Gehring, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.800070 · Cited by 13
Rivera, J., Girón, N., & José, E. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020488 · Cited by 12
Can T Cells Abort SARS-CoV-2 and Other Viral Infections?
Swadling, L., & Maini, M. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054371 · Cited by 13
Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose
Perico, L., Todeschini, M., Casiraghi, F., Mister, M., Pezzotta, A., Peracchi, T., Tomasoni, S., Trionfini, P., Benigni, A., & Remuzzi, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123158 · Cited by 12
Considerations for Choosing T Cell Assays during a Pandemic
Law, J. C., & Watts, T. H. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300129 · Cited by 11
Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines
Yue, C., Wang, P., Tian, J., Gao, G. F., Liu, K., & Liu, W. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.80468 · Cited by 12
Modeling the Within-Host Dynamics of SARS-CoV-2 Infection Based on Antiviral Treatment
Song, T., Wang, Y., Gu, X., & Qiao, S. (2023) · Mathematics · doi:10.3390/math11163485 · Cited by 12
Balinsky, C. A., Jiang, L., Jani, V., Cheng, Y., Zhang, Z., Belinskaya, T., Qiu, Q., Long, T. K., Schilling, M. A., Jenkins, S. A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1266829 · Cited by 15
Chakraborty, C., Bhattacharya, M., & Lee, S. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2526 · Cited by 14
Highly conserved Betacoronavirus sequences are broadly recognized by human T cells
Neto, T. A. P., Zmasek, C. M., Avalos, L., Sidney, J., Trevizani, R., Phillips, E. J., Mallal, S. A., Frazier, A., Tan, G. S., Scheuermann, R. H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.07.015 · Cited by 13
Casado, J. L., Häemmerle, J., Vizcarra, P., Velasco, H., Velasco, T., Fernández-Escribano, M., & Vallejo, A. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.02.020 · Cited by 12
Konik, M., Lindemann, M., Zettler, M., Meller, L., Dolff, S., Rebmann, V., Horn, P. A., Dittmer, U., Krawczyk, A., Schipper, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194606 · Cited by 13
Mele, D., Calastri, A., Maiorano, E., Cerino, A., Sachs, M., Oliviero, B., Mantovani, S., Baldanti, F., Bruno, R., Benazzo, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748881 · Cited by 13
Pompsch, M., Fisenkci, N., Horn, P. A., Kraemer, M., & Lindemann, M. (2021) · Neurological Research and Practice · doi:10.1186/s42466-021-00158-5 · Cited by 12
DJ‐1 depletion prevents immunoaging in T‐cell compartments
Zeng, N., Capelle, C., Baron, A., Kobayashi, T., Cire, S., Tslaf, V., Leonard, C., Coowar, D., Koseki, H., Westendorf, A. M., et al. (2022) · EMBO Reports · doi:10.15252/embr.202153302 · Cited by 13
Park, H.-S., Matsuoka, Y., Luongo, C., Yang, L., Santos, C. P., Liu, X., Ahlers, L. R. H., Moore, I. N., Afroz, S., Johnson, R. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00493-x · Cited by 12
Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic
Sun, Y., Luo, B., Liu, Y., Wu, Y., & Chen, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130398 · Cited by 13
Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
Phan, J. M., Layton, E. D., Yu, K. K. Q., Aguilar, M. S., Golez, I., Franko, N., Logue, J. K., Rodda, L. B., Howard, C. A., Pepper, M., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200815 · Cited by 12
Chu, C., Schönbrunn, A., Fischer, D., Liu, Y., Hocher, J.-G., Weinerth, J., Klemm, K., von Baehr, V., Krämer, B. K., Elitok, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187880 · Cited by 13
T cell control of SARS-CoV-2: When, which, and where?
Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12
Bolourian, A., & Mojtahedi, Z. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.10.012 · Cited by 12
Schöllhorn, A., Schuhmacher, J., Besedovsky, L., Fendel, R., Jensen, A. T. R., Stevanović, S., Lange, T., Rammensee, H., Jan Born, A., Gouttefangeas, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626308 · Cited by 9
Kobayashi, K., Tachibana, M., & Tsutsumi, Y. (2021) · Innate Immunity · doi:10.1177/17534259211043159 · Cited by 11
Sherman, A. C., Crombie, J. L., Cheng, C., Desjardins, M., Zhou, G., Ometoruwa, O., Rooks, R., Senussi, Y., McDonough, M. M., Guerrero, L. I., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac417 · Cited by 12
Analysis of the Tropism of SARS-CoV-2 Based on the Host Interactome of the Spike Protein
Bamberger, C., Pankow, S., Martínez‐Bartolomé, S., Diedrich, J. K., Park, S. K. R., & Yates, J. R. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00387 · Cited by 12
Meyer, M., Wang, Y., Edwards, D. K., Smith, G. R., Rubenstein, A. B., Ramanathan, P., Mire, C. E., Pietzsch, C. A., Chen, X., Ge, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.25.428136 · Cited by 12
The Host Interactome of Spike Expands the Tropism of SARS-CoV-2Preprint
Bamberger, C., Pankow, S., Martínez‐Bartolomé, S., Diedrich, J. K., Park, S. K. R., & Yates, J. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.16.431318 · Cited by 12
Yin, D., Han, Z., Lang, B., Li, Y., Mai, G., Chen, H., Feng, L., Chen, Y.-Q., Luo, H., Xiong, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195533 · Cited by 12
Baldwin, J., Noorali, S., & Vaseashta, A. (2023) · COVID · doi:10.3390/covid3090089 · Cited by 14
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Abela, I. A., Schwarzmüller, M., Ulytė, A., Radtke, T., Haile, S. R., Ammann, P., Raineri, A., Rueegg, S., Epp, S., Berger, C., et al. (2024) · mBio · doi:10.1128/mbio.02722-23 · Cited by 10
Martins, B. R., Ratkevicius, C. M. A., Simão, G. F., Martins, R. D. P., de Faria, L. V., Matias, T. A., Rodrigues, V., Muñoz, R. A. A., & Alves, R. P. (2024) · Biosensors · doi:10.3390/bios14110514 · Cited by 13
Amini, A., Garner, L. C., Shaw, R. H., Kelly, N. E. W., Adele, S., Skelly, D., Dejnirattisai, W., Greenland, M., Liu, X., Heslington, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu3337 · Cited by 12
Grundlagen der Replikation und der Immunologie von SARS-CoV-2
Ueffing, M., Bayyoud, T., Schindler, M., & Ziemssen, F. (2020) · Der Ophthalmologe · doi:10.1007/s00347-020-01155-w · Cited by 13
How strong is the evidence that it is possible to get SARS‐CoV‐2 twice? A systematic review
Farrukh, L., Mumtaz, A., & Sana, M. K. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2203 · Cited by 10
The strand-biased transcription of SARS-CoV-2 and unbalanced inhibition by remdesivir
Zhao, Y., Sun, J., Li, Y., Li, Z., Xie, Y., Feng, R., Zhao, J., & Hu, Y. (2021) · iScience · doi:10.1016/j.isci.2021.102857 · Cited by 16
Adaptive immune responses to SARS-CoV-2
Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 11
BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease
Rossi, C., Lanuti, P., Cicalini, I., Bellis, D. D., Pierdomenico, L., Boccio, P. D., Zucchelli, M., Natale, L., Sinjari, B., Catitti, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9101164 · Cited by 11
da Silva, L. T., Ortega, M. M., Tiyo, B. T., Viana, I. F. T., de Lima, T. E., Tozetto‐Mendoza, T. R., Oliveira, L. M. D. S., Teixeira, F. M. E., Lins, R. D., de Almeida, A., et al. (2021) · Clinics · doi:10.6061/clinics/2021/e3548 · Cited by 9
Donzelli, S., Spinella, F., Domenico, E. G. D., Pontone, M., Cavallo, I., Orlandi, G., Iannazzo, S., Ricciuto, G. M., ISG Virology Covid Team, Pellini, R., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.01.021 · Cited by 11
Kumar, S., Saxena, S. K., Maurya, V. K., & Tripathi, A. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.804808 · Cited by 12
Al-Hamamy, H. R. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00076 · Cited by 11
Kowalski, E., Stengel, A., Schneider, A., Goebel‐Stengel, M., Zipfel, S., & Graf, J. (2022) · Vaccines · doi:10.3390/vaccines10030455 · Cited by 11
Human seasonal coronavirus neutralization and COVID‐19 severity
Wells, D. A., Cantoni, D. M., Neto, M. M., Genova, C. D., Sampson, A., Ferrari, M., Carnell, G., Nadesalingam, A., Smith, P., Chan, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27937 · Cited by 12
Sejdic, A., Frische, A., Jørgensen, C. S., Rasmussen, L. D., Trebbien, R., Dungu, A. M., Holler, J. G., Ostrowski, S. R., Eriksson, R., Søborg, C., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-01974-8 · Cited by 11
Yoshifuji, A., Toda, M., Ryuzaki, M., Oyama, E., Kikuchi, K., Kawai, T., Sakai, K., Koinuma, M., Katayama, K., Yokoyama, T., et al. (2023) · Vaccines · doi:10.3390/vaccines11030653 · Cited by 11
Pandey, V. K., Tripathi, A., Srivastava, S., Pandey, S., Dar, A. H., SINGH, R. K., Duraisamy, P., Singh, P., & Shaikh, A. M. (2023) · Applied Food Research · doi:10.1016/j.afres.2023.100291 · Cited by 14
COVID ‐19 and primary wound healing: A new insights and advance
Li, D., Cao, W., Zhou, Q., Wu, X., Song, X., & Qin, H. (2023) · International Wound Journal · doi:10.1111/iwj.14324 · Cited by 10
Tehrani, H. A., Darnahal, M., Nadji, S. A., & Haghighi, S. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100830 · Cited by 11
Corrao, S., Gervasi, F., Bernardo, F. D., Natoli, G., Raspanti, M., Catalano, N., & Argano, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040849 · Cited by 11
Khanolkar, A. (2021) · Cells · doi:10.3390/cells11010067 · Cited by 12
Esparcia-Pinedo, L., Martínez‐Fleta, P., Ropero, N., Vera-Tomé, P., Reyburn, H. T., Casasnovas, J. M., Rodríguez-Frade, J. M., Valés‐Gómez, M., Vilches, C., Martín‐Gayo, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755891 · Cited by 11
AlMalki, F. A., Albukhaty, S., Alyamani, A. A., Khalaf, M. N., & Thomas, S. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-18868-x · Cited by 13
Limited Recognition of Highly Conserved Regions of SARS-CoV-2
Swaminathan, S., Lineburg, K. E., Ambalathingal, G. R., Crooks, P., Grant, E. J., Mohan, S. V., Raju, J., Panikkar, A., Texier, L. L., Tong, Z. W. M., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02780-21 · Cited by 11
Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic
Wang, G., Xiang, Z., Wang, W., & Chen, Z. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200049 · Cited by 12
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2021) · medRxiv · doi:10.1101/2021.05.04.21256571 · Cited by 11
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-309746/v1 · Cited by 12
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01614-w · Cited by 29
Boesch, M., Sykora, M. M., Gasteiger, S., Baty, F., Brutsche, M. H., & Sopper, S. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24481 · Cited by 10
Zhou, H., Leng, P., Wang, Y., Yang, K., Li, C., Ojcius, D. M., Wang, P., & Jiang, S. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.02.041 · Cited by 10
Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization
Ragone, C., Mauriello, A., Cavalluzzo, B., Cavalcanti, E., Russo, L., Manolio, C., Mangano, S., Cembrola, B., Tagliamonte, M., & Buonaguro, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398002 · Cited by 11
Samaan, P., Korosec, C. S., Budylowski, P., Chau, S., Pasculescu, A., Qi, F., Delgado-Brand, M., Tursun, T. R., Mailhot, G., Dayam, R. M., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01685-24 · Cited by 11
Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19
Hausdorff, W. P., & Flores, J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.171 · Cited by 10
Smit, W. L., van Tol, S., van der Wal, S., van Vulpen, F., la Grouw, S., van Lelyveld, L., Limonard, G. J. M., Bossink, A. W. J., Godeke, G.-J., Shrestha, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839367 · Cited by 10
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 9
Costa, C. S., Scozzari, G., Migliore, E., Galassi, C., Ciccone, G., Ricciardelli, G., Scarmozzino, A., Angelone, L., Cassoni, P., Cavallo, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10071031 · Cited by 11
Wang, L., Candia, J., Ma, L., Zhao, Y., Imberti, L., Sottini, A., Quirós-Roldán, E., Dobbs, K., Burbelo, P. D., Cohen, J. I., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78002 · Cited by 10
Nelde, A., Rieth, J., Roerden, M., Dubbelaar, M. L., Gravel, N. H., Bauer, J., Klein, R., Hoheisel, T., Mahrhofer, H., Göpel, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105643 · Cited by 11
Abdelaziz, M. O., Raftery, M. J., Weihs, J., Bielawski, O., Edel, R., Köppke, J. K. C., Vladimirova, D., Adler, J. M., Firsching, T. C., Voß, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166765 · Cited by 10
m6A methylation: a potential key player in understanding and treating COVID-2019 infection
Qian, W., Zhou, J., Duan, L., Wang, H., Xu, S., & Cao, Y. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01580-1 · Cited by 10
Juhn, Y. J., Wi, C., Ryu, E., Sampathkumar, P., Takahashi, P. Y., Yao, J. D. C., Binnicker, M. J., Natoli, T. L., Evans, T. K., King, K. S., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.016 · Cited by 10
A Perspective on COVID-19 Management
Pavelić, K., Pavelić, S. K., Brix, B., & Goswami, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081586 · Cited by 12
DiMuzio, J. M., Heimbach, B. C., Howanski, R. J., Dowling, J. P., Patel, N. B., Henriquez, N., Nicolescu, C., Nath, M., Polley, A. M., Bingaman, J. L., et al. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100098 · Cited by 9
Eslami, S., Glassy, M. C., & Ghafouri‐Fard, S. (2021) · Gene · doi:10.1016/j.gene.2021.146113 · Cited by 12
Activation of mucosal immunity and novel prophylactic and therapeutic strategy in combating COVID-19
Chatterjee, S. K., Saha, S., & Muñoz, M. N. M. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00025 · Cited by 11
Laurén, I., Havervall, S., Ng, H., Lord, M., Pettke, A., Greilert‐Norin, N., Gabrielsson, L., Chourlia, A., Amoêdo‐Leite, C., Josyula, V. S., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.595 · Cited by 9
Markewitz, R. D. H., Juhl, D., Pauli, D., Görg, S., Junker, R., Rupp, J., Engel, S., Steinhagen, K., Herbst, V., Zapf, D., et al. (2022) · Vaccines · doi:10.3390/vaccines10050649 · Cited by 10
Tsukinoki, K., Yamamoto, T., Saito, J., Sakaguchi, W., Iguchi, K., Inoue, Y., Ishii, S., Sato, C., Yokoyama, M., Shiraishi, Y., et al. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.13011 · Cited by 10
Pradenas, E., Ubals, M., Urrea, V., Suñer, C., Trinité, B., Riveira‐Muñoz, E., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.860215 · Cited by 9
Husby, A., Corn, G., & Krause, T. G. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.32.2101096 · Cited by 9
SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronavirusesPreprint
Stervbo, U., Rahmann, S., Roch, T., Westhof, T., & Babel, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.01.182741 · Cited by 10
Kusnadi, A., Ramírez-Suástegui, C., Fajardo, V., Chee, S., Meckiff, B. J., Simon, H. A., Pelosi, E., Seumois, G., Ay, F., Vijayanand, P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.194027 · Cited by 10
Pérez‐Cabezas, B., Ribeiro, R. J. T., Costa, I., Esteves, S., Teixeira, A. R., Reis, T., Monteiro, R., Afonso, A., Pinheiro, V. C. A., Antunes, M. I., et al. (2021) · medRxiv · doi:10.1101/2021.01.04.20248897 · Cited by 11
Potential global impact of the N501Y mutation on MHC-II presentation and immune escapePreprint
Castro, A., Carter, H. K., & Zanetti, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.02.429431 · Cited by 10
Chang-Rabley, E., van Zelm, M. C., Ricotta, E., & Edwards, E. S. J. (2024) · Vaccines · doi:10.3390/vaccines12060675 · Cited by 10
Rodríguez‐Ubreva, J., Calafell-Segura, J., Calvillo, C. L., Keller, B., Ciudad, L., Handfield, L., de la Calle‐Fabregat, C., Godoy‐Tena, G., Andrés‐León, E., Hoo, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54732-x · Cited by 14
Tu, T. H., Bennani, F. E., Masroori, N., Liu, C., Nemati, A., Rozza, N., Grunbaum, A., Kremer, R. B., Milhalcioiu, C., Roy, D., et al. (2025) · Communications Biology · doi:10.1038/s42003-024-07350-8 · Cited by 9
SARS-CoV-2 Vaccines: ‘Warp Speed’ Needs Mind Melds not Warped Minds
Moore, J. P., & Klasse, P. J. (2020) · Cited by 9
The Influence of Immune Immaturity on Outcome After Virus Infections
Shaw, E. R., & Su, H. C. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.11.016 · Cited by 11
Vitiello, L., Gatta, L., Ilari, S., Bonassi, S., Cristina, M., Ciatti, F., Fini, M., Proietti, S., Russo, P., Tomino, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836495 · Cited by 10
Romano, A., Parrinello, N. L., Barchitta, M., Manuele, R., Puglisi, F., Maugeri, A., Barbato, A., Triolo, A. M., Giallongo, C., Tibullo, D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11157-0 · Cited by 10
Calcoen, B., Callewaert, N., Vandenbulcke, A., Kerstens, W., Imbrechts, M., Vercruysse, T., Dallmeier, K., Weyenbergh, J. V., Maes, P., Bossuyt, X., et al. (2022) · Viruses · doi:10.3390/v14061257 · Cited by 8
Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection
Chu, C., Schönbrunn, A., Klemm, K., von Baehr, V., Krämer, B. K., Elitok, S., & Hocher, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915001 · Cited by 9
The m7G Modification Level and Immune Infiltration Characteristics in Patients with COVID-19
Lu, L., Zheng, J., Liu, B., Wu, H., Huang, J., Wu, L., & Li, D. (2022) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s385050 · Cited by 10
Francis, M. E., Jansen, E. B., Yourkowski, A., Selim, A., Swan, C. L., MacPhee, B. K., Thivierge, B. M., Buchanan, R. M., Lavender, K. J., Darbellay, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41761-1 · Cited by 11
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
